The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index; 11 of the 138 sources its claims cite were checked for support.
Postural Orthostatic Tachycardia Syndrome: Mechanisms and New Therapies
Abstract
Postural orthostatic tachycardia syndrome (POTS) is a clinically heterogeneous disorder with multiple contributing pathophysiologic mechanisms manifesting as symptoms of orthostatic intolerance in the setting of orthostatic tachycardia (increase in heart rate by at least 30 beats per minute upon assuming an upright position) without orthostatic hypotension. The three major pathophysiologic mechanisms include partial autonomic neuropathy, hypovolemia, and hyperadrenergic state. Patients often will exhibit overlapping characteristics from more than one of these mechanisms. The approach to the treatment of POTS centers on treating the underlying pathophysiologic mechanism. Stockings, abdominal binders, and vasoconstrictors are used to enhance venous return in partial neuropathic POTS. Exercise and volume expansion are the main treatment strategies for hypo-volemic POTS. For hyperadrenergic POTS, beta-blockers and avoidance of norepinephrine reuptake inhibitors is important. Attempts should be made to discern which pathophysiologic mechanism(s) may be afflicting patients so that treatment regimens can be individualized.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
Postural orthostatic tachycardia syndrome (POTS) is a clinically heterogeneous disorder defined by an upright heart rate increase of at least 30 bpm without orthostatic hypotension, with three major overlapping pathophysiologic endophenotypes: partial autonomic neuropathy, hypovolemia, and hyperadrenergic state. Treatment should be individualized to the underlying mechanism(s), using nonpharmacologic and pharmacologic strategies such as compression, volume expansion, exercise, beta-blockers, and avoidance of norepinephrine reuptake inhibitors.
Key findings
- POTS is estimated to affect 0.5–3 million individuals in the United States; >90% of patients are young, white women of childbearing age, and symptoms must persist for at least 3–6 months without another chronic condition or medication causing orthostatic intolerance.
- The three major endophenotypes are neuropathic POTS (partial autonomic neuropathy with lower-extremity, pelvic, and splanchnic blood pooling), hypovolemic POTS (13–22% lower plasma or blood volume, renin-aldosterone paradox, and Ang-II levels 2–3 times higher in some patients), and hyperadrenergic POTS (upright plasma norepinephrine often exceeding 800 pg/ml versus approximately 400–500 pg/ml in healthy controls).
- Treatment is mechanism-targeted: midodrine 5–10 mg acutely reduced heart rate from 108 bpm to 95 bpm in 13 POTS patients; 3 months of exercise training led 50–70% of completers to no longer meet POTS criteria, though only 41% of community patients completed a standardized program; hyperadrenergic POTS treatment includes beta-blockers, pyridostigmine, ivabradine, and avoidance of NRIs, SSRIs, or SNRIs.
- Patients often exhibit overlapping features from more than one endophenotype, and no single all-unifying pathophysiologic mechanism exists; POTS may be a final common pathway for several interrelated mechanisms.
Methods
- Narrative review of the literature on POTS mechanisms and therapies; no primary data collection, systematic search strategy, or meta-analysis is described.
- Synthesizes prior studies into three pathophysiologic endophenotypes and a treatment table, citing small prospective studies, randomized trials, retrospective analyses, and case series.
- Main analysis is qualitative mechanistic and therapeutic synthesis rather than formal quantitative analysis.
Limitations
- Stated in the paper: the exact prevalence of POTS is unknown; an all-inclusive pathophysiologic mechanism remains elusive; treatment knowledge has advanced mainly through small prospective studies; some agents are not well studied in POTS (e.g., fludrocortisone, droxidopa, ivabradine lacks a prospective comparator study); and exercise adherence is limited, with only 41% completing a standardized 3-month program.
- Evident from the text: as a narrative review, it does not systematically assess study quality, risk of bias, or publication bias, and many cited studies are small, retrospective, uncontrolled, or case series.
- Evident from the text: findings from special populations (e.g., astronauts, cosmonauts, Ehlers-Danlos syndrome patients, children) may not generalize to all POTS patients, and recommendations rely on synthesis and expert opinion rather than new empirical data.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
89 Not checked yet · 12 Own interpretation · 5 Partly supported · 2 No basis given · 1 Supported · 1 Not supported · accuracy not yet measured
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“While many conditions, such as mast cell activation disorders (9), Ehlers-Danlos syndrome (10, 11), deconditioning (12), and genetic mutations of norepinephrine transporters (13), coexist with POTS, their downstream effects also funnel into these three principal pathophysiologic mechanisms.”
What the sources say
- Not checked yetcites [9] source
- Not checked yetcites [10] source
- Partly supportedcites [11] sourceExperimental — accuracy not yet measured
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Partly supportedcites [13] sourceExperimental — accuracy not yet measured
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Neuronal nitrous oxide synthase, and not endothelial nitrous oxide synthase, was determined to be responsible for causing this phenomenon (29).”
What the sources say
- Partly supportedcites [29] sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says selective nNOS inhibition blunted the local-heating response and that reduced nNOS-derived nitric oxide appears to account for the NO deficit in low-flow POTS, while eNOS function appears intact. These are qualified interpretations, not a determination that nNOS alone causes the phenomenon or that eNOS has no role. (LLM, conf=0.82)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Other studies have also demonstrated that POTS patients have significantly greater decreases in thoracic and cerebral blood flow when compared to healthy controls during tilt (21, 23, 25-27).”
What the sources say
- Partly supportedcites [21] sourceExperimental — accuracy not yet measured
The Results (page unavailable) report that thoracic blood flow decreased during tilt in all subjects and that thoracic blood volume was significantly smaller in POTS patients than in controls at 35° and 70°. They do not establish a significantly greater decrease in thoracic blood flow in POTS patients, and the paper does not report cerebral blood flow during tilt. (LLM, conf=0.85)
- Partly supportedcites [23] sourceExperimental — accuracy not yet measured
The Upright Tilt Data results report a significantly reduced change in central blood volume in all POTS groups, but this is a measure of volume, not thoracic blood flow. They also report significantly decreased cerebral blood flow velocity during tilt only in the POTS-hyperventilation group, not in all POTS patients. (LLM, conf=0.88)
- Not checked yetcites [25] source
- Partly supportedcites [26] sourceExperimental — accuracy not yet measured
The HUT With Transcranial Doppler results report a significant decrease in cerebral blood-flow velocity during tilt in patients with idiopathic orthostatic intolerance. The paper does not establish that this decrease was greater than in healthy controls, and it does not report thoracic blood flow. Its Discussion also cautions that Doppler measures flow velocity rather than blood flow directly; page numbers are unavailable in our copy. (LLM, conf=0.88)
- Partly supportedcites [27] sourceExperimental — accuracy not yet measured
The Results (page unavailable) report a significantly greater decrease in cerebral blood-flow velocity during tilt in POTS subjects than in controls (19.5% versus 10.3%, P < 0.05). The paper does not report a corresponding comparison of thoracic blood flow, so it supports only the cerebral part of the claim. The Methods limit the studied POTS group to young, normocapnic subjects. (LLM, conf=0.90)
boostedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“POTS patients will sometimes manifest features from more than one of the three major POTS endophenotypes (4).”
What the sources say
- Partly supportedcites [4] sourceExperimental — accuracy not yet measured
In “Need to Better Understand the Pathophysiologies Underlying POTS” (page unavailable), the paper says multiple underlying mechanisms can lead to POTS and several comorbid diagnoses can coexist in one patient. It does not identify three major POTS endophenotypes or state that patients manifest features of more than one; it instead calls for agreed-upon criteria for endophenotypes. (LLM, conf=0.81)
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Not surprisingly, midodrine has been shown to be more effective in treating neuropathic POTS than hyperadrenergic POTS (56).”
What the sources say
- Supportedcites [56] source
The Discussion (Main findings; page not provided) reports that midodrine improved postural tachycardia versus placebo in neuropathic POTS but not hyperadrenergic POTS. The Summary and practical significance likewise says hyperadrenergic subjects responded similarly to midodrine and placebo. (LLM, conf=0.94)
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Patients often will exhibit overlapping characteristics from more than one of these mechanisms.”
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Jacob et al. (18) demonstrated significantly impaired sympathetic nervous system activity in the lower extremities of POTS patients.”
What the sources say
- Not checked yetcites [18] source
boostedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“In contrast, the amounts of norepinephrine released in the upper extremities in response to the same stimuli were no different between POTS patients and healthy controls.”
What the sources say
- Not checked yetcites [18] source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The three major pathophysiologic mechanisms include partial autonomic neuropathy, hypovolemia, and hyperadrenergic state.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Stewart et al. (14-17) noted that pediatric patients with POTS had excessive pooling of blood in the lower extremities, primarily due to arteriolar dysregulation rather than inappropriately increased venous capacitance.”
What the sources say
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Amounts of norepinephrine released at sympathetic nervous system synapses in the lower extremities in response to a cold pressor test, a nitroprusside infusion, and a tyramine infusion were markedly lower in POTS patients than in healthy controls.”
What the sources say
- Not checked yetcites [18] source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“The extent of partial autonomic neuropathy extends beyond the lower extremities into the pelvic and splanchnic circulation.”
What the sources say
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Both Doppler ultrasound and plethysmography studies have demonstrated abnormally increased blood flow and pooling in the splanchnic and pelvic circulation of POTS patients both at rest and in an upright position (20-24).”
What the sources say
boostedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Thus far, the literature has identified three different pathophysiologic mechanisms that are capable of manifesting the POTS phenotype: ( a ) partial autonomic neuropathy, ( b ) persistent predilection for hypovolemia, and ( c ) central hyperadrenergic state.”
What the sources say
- Not checked yetcites [4] source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“These three pathophysiologic mechanisms engender somewhat distinct variants of the POTS phenotype that henceforward will be referred to as endophenotypes (4).”
What the sources say
- Not checked yetcites [4] source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Further investigations into the renin-angiotensin aldosterone system (RAAS) revealed that plasma angiotensin 2 (Ang-II) levels in some POTS patients are elevated (on the order of 2-3 times higher) when compared to healthy controls (35, 36).”
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Evidence of autoantibodies that act as partial alpha-1 antagonists have also been found in POTS patients (32).”
What the sources say
- Not checked yetcites [32] source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Despite these low blood and plasma volumes, plasma renin activity and aldosterone levels are also inappropriately low in POTS patients.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Despite their high Ang-II levels, POTS patients are paradoxically prone to hypovolemia (37).”
What the sources say
- Not checked yetcites [37] source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Studies have shown that some POTS patients have 13-22% less plasma or blood volume than do healthy controls (33-35).”
What the sources say
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“A significant portion of POTS patients suffer from a state of persistent hypovolemia.”
What the sources say
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“The decrease in stroke volume, as predicted by the Starling curve, was out of proportion to the degree of plasma volume reduction (41).”
What the sources say
- Not checked yetcites [41] source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“This is supported by the finding that POTSpatients have an attenuated hypertensive response to Ang-II versus healthy control subjects after infusion of a standardized dose of Ang-II (38).”
What the sources say
- Not checked yetcites [38] source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Medow et al. (28) found defective cutaneous vasodilation of the microvasculature mediated by nitric oxide with local heating in POTS patients versus healthy control subjects.”
What the sources say
- Not checked yetcites [28] source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“This finding suggests that deconditioning, with its subsequent plasma volume reduction and decreased stroke volume, may play a significant role in the development of a POTS phenotype (42).”
What the sources say
- Not checked yetcites [42] source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“A significant proportion of patients with Ehlers-Danlos syndrome exhibit autonomic dysfunction and orthostatic intolerance (11).”
What the sources say
- Not checked yetcites [11] source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“De Wandele et al. (30) performed autonomic function testing in 39 patients with Ehlers-Danlos syndrome and found that orthostatic intolerance was much more common in this population.”
What the sources say
- Not checked yetcites [30] source
plaincorrelationaln = 39- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Levine et al. (39) demonstrated that in six previously healthy male astronauts, just 16 days of spaceflight resulted in a decrease in blood volume of nearly 6% (39).”
What the sources say
- Not checked yetcites [39] source
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“These could have an effect similar to a partial autonomic neuropathy due to inadequate vasoconstriction in response to alpha-adrenergic stimulation ( Figure 1 ).”
What the sources say
- Not checked yetcites [32] source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Additionally, the aldosterone:renin ratio was found to be lower in POTS patients than in healthy control subjects (34).”
What the sources say
- Not checked yetcites [34] source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Mast cell activation disorders are another condition that frequently coexists with POTS (9).”
What the sources say
- Not checked yetcites [9] source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Graded compression garments and abdominal binders have improved symptoms of orthostatic intolerance in conditions associated with excessive blood pooling (52, 53).”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“One of the twins even became hypertensive with standing (13).”
What the sources say
- Not checked yetcites [13] source
plaindirectSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Hyperadrenergic POTS is an important endophenotype of POTS with the characteristic, neurohormonal hallmark of elevated upright plasma norepinephrine (34, 36).”
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Administration of reboxetine, a norepinephrine transporter inhibitor, to healthy controls provoked hemodynamic changes consistent with POTS (48).”
What the sources say
- Not checked yetcites [48] source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Supine levels of norepinephrine are similar between healthy controls and POTS patients (34).”
What the sources say
- Not checked yetcites [34] source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Higher levels of autoantibodies against beta-1 and beta-2 adrenoreceptors have been detected in POTS patients versus healthy controls in serologic studies (32, 44).”
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This is likely due to the contribution of multiple pathophysiologic mechanisms to their unique phenotype, resulting in the clinical heterogeneity seen in this syndrome.”
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Octreotide, a subcutaneously injectable somatostatin analog that causes vasoconstriction in the splanchnic vascular bed, has also been studied in POTS patients (59).”
What the sources say
- Not checked yetcites [59] source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“In a study of patients with autonomic failure, abdominal compression of 40 mmHg was as effective as midodrine (53).”
What the sources say
- Not checked yetcites [53] source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Administration of 5-10 mg doses acutely reduced both supine and upright heart rate (from 108 bpm to 95 bpm) in 13 patients with POTS.”
What the sources say
- Not checked yetcites [54] source
plaindirectn = 13- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“This group also demonstrated that autoantibody affinity toward beta-receptors positively correlated with a greater degree of orthostatic tachycardia (44).”
What the sources say
- Not checked yetcites [44] source
boostedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“The combination of abdominal binders and lower extremity compression stockings is thought to be more effective than lower extremity compression alone due to the disproportionally greater volume in the splanchnic circulation than in the legs (51).”
What the sources say
- Not checked yetcites [51] source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Alteration of norepinephrine metabolism, congenital or iatrogenic, is another well-described cause of hyperadrenergic POTS.”
What the sources say
- Not checked yetcites [13] source
boosteddirectn = 2- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“POTS may simply be a final common pathway for several interrelated pathophysiologic mechanisms (50).”
What the sources say
- Not checked yetcites [50] source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“The binding of these autoantibodies to the adrenergic receptors is postulated to drive the tachycardia in some POTS patients (32).”
What the sources say
- Not checked yetcites [32] source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In this endophenotype, the predominant symptom is palpitations due to orthostatic tachycardia that is primarily driven by a hyperadrenergic state.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Levels of plasma epinephrine appear to be similar between POTS patients and healthy subjects (34, 36).”
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Another study demonstrated that epigenetic modification of the SCL6A2 gene resulting in its downregulation was more prevalent in POTS patients than in healthy controls (45).”
What the sources say
- Not checked yetcites [45] source
boostedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“An all-unifying pathophysiologic mechanism does not exist.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“In certain cases, it may be possible to recognize key endophenotypes (13, 73, 79).”
What the sources say
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Erythropoietin does not appear to improve the orthostatic tachycardia of POTS (71, 72)”
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Modafinil, an agent that is used to treat narcolepsy and promote wakefulness, can sometimes help with fatigue in POTS patients.”
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“In fact, 50-70% of POTS patients who complete 3 months of endurance training exhibit hemodynamic changes that no longer meet criteria for POTS (42, 62, 63).”
What the sources say
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“pyridostigmine has been shown to improve orthostatic tachycardia in POTS patients.”
plaindirectn = 17- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Patients often report significant delays in diagnosis, exceeding five years between the onset of symptoms and eventual diagnosis in many cases.”
What the sources say
- Not checked yetcites [2] source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Central-acting sympatholytic agents, such as clonidine and methyldopa, have also been used in POTS patients and likely work by decreasing central sympathetic nerve traffic.”
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“The short-term administration of oral DDAVP and water to POTS patients resulted in standing heart rates significantly lower than that after placebo administration (69).”
What the sources say
- Not checked yetcites [69] source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Acute infusions of normal saline have been shown to afford rapid relief in patients with POTS crisis (8, 54)”
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Higher levels of plasma copeptin, a peptide fragment of arginine vasopressin, which is a neurohormonal marker for relative hypovolemia, have been shown to positively correlate with treatment response to midodrine in POTS patients (73).”
What the sources say
- Not checked yetcites [73] source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“One small prospective study demonstrated that, in POTS patients, six consecutive days of a low-sodium diet (10 mEq/day) resulted in significantly greater orthostatic tachycardia than six consecutive days of a high-sodium diet (300 mEq/day), highlighting the importance of sodium intake (66).”
What the sources say
- Not checked yetcites [66] Raj S, 2014, Heart Rhythm
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Fludrocortisone, a synthetic aldosterone analog that causes sodium retention, is considered the mainstay pharmacologic agent for volume expansion in patients with orthostatic intolerance and hypotension (68).”
What the sources say
- Not checked yetcites [68] source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Small case series have shown that ivabradine reduces upright heart rate and improves symptoms associated with orthostatic intolerance (83, 84).”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“especially in light of studies that suggest the true prevalence of psychiatric disorders in this patient population may be no different than in the general population (75).”
What the sources say
- Not checked yetcites [75] source
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Further studies have also demonstrated long-term benefits with using pyridostigmine in POTS patients (81, 82).”
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Given the high incidence of polypharmacy in POTS patients (10), coupled with the perception of increased depression in POTS patients (74), antidepressant use is likely high in this patient population.”
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“a small prospective study of patients who failed beta-blockers demonstrated reductions in upright norepinephrine levels and increased plasma volume by 12% on doses of clonidine 0.3-0.4 mg/day (86).”
What the sources say
- Not checked yetcites [86] source
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“In contrast, Fu et al. (64) showed that the long-acting, once-daily formulation of propranolol did not improve quality of life at one month.”
What the sources say
- Not checked yetcites [64] source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Supine and upright blood pressures were no different between the group that received pyridostigmine and the placebo group.”
What the sources say
- Not checked yetcites [80] source
plainn = 17- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Zhao et al. (79) demonstrated that POTS patients with low copeptin levels were far more likely to respond to metoprolol than those with high levels of copeptin, presumably due to a greater contribution of the hyperadrenergic endophenotype to their syndrome.”
What the sources say
- Not checked yetcites [79] source
boostedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“A large randomized prospective study demonstrated that propranolol, bisoprolol, propranolol + pyridostigmine, and bisoprolol + pyridostigmine all resulted in improvements in the Orthostatic Intolerance questionnaire, the Beck depression inventory, and the physical component of the SF-36 (77).”
What the sources say
- Not checked yetcites [77] source
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Unfortunately, only 41% of POTS patients in the community setting are able to complete a standardized 3-month program involving mild-moderate intensity endurance training 3-5 times per week at 30-45 min per session (63).”
What the sources say
- Not checked yetcites [63] source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“The main limitation of pyridostigmine's use is adverse gastrointestinal effects, which can include diarrhea, cramping, nausea, vomiting, and flatulence (70).”
What the sources say
- Not checked yetcites [70] source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“In a study of 17 POTS patients, symptoms and standing heart rate were significantly reduced after pyridostigmine administration versus placebo in the acute setting (80).”
What the sources say
- Not checked yetcites [80] source
plaindirectn = 17- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“but this approach is not sustainable in the long-term due to the potential for vascular access complications (67).”
What the sources say
- Not checked yetcites [67] source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Kpaeyeh et al. (87) demonstrated that modafinil 100 mg did not significantly increase the acute supine or upright heart rate in POTS patients compared to placebo.”
What the sources say
- Not checked yetcites [87] source
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The mainstay of sympathetic nervous system suppression is beta-blockers.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- It may state two separate claims as one. 30
- Probably not a substantial claim. 4
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“This cutaneous vasodilation is mediated by nitric oxide, as the addition of a nitric oxide synthase inhibitor blunts the vasodilation in both POTS patients and healthy controls to the same degree.”
What the sources say
- Disputedcites [28] sourceExperimental — accuracy not yet measured
The Results (Cutaneous Hyperemia and Endothelial Dysfunction) report that L-NAME blunted the thermal-hyperemia plateau in reference subjects but did not substantially affect the already attenuated plateau in a low-flow POTS patient; the grouped data confirmed this pattern. Normal-flow POTS responses were similar to reference responses, so the paper does not find the same degree of blunting across POTS patients and controls. (LLM, conf=0.92)
Checked by a reasoning model — may be wrong.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Exercise is the only intervention that has been shown to improve the aldosterone:renin ratio and increase plasma and blood volumes chronically (64).”
What the sources say
- Partly supportedcites [64] sourceExperimental — accuracy not yet measured
The Results (Exercise Training; page unavailable) report that three months of training increased plasma and blood volumes and modestly increased the aldosterone-to-renin ratio in POTS patients. The Results (Propranolol Treatment; page unavailable) report neither change with propranolol. The paper compares exercise with propranolol and placebo, so it does not establish that exercise is the only intervention capable of these effects. (LLM, conf=0.88)
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Postural orthostatic tachycardia syndrome (POTS) is a clinically heterogeneous disorder with multiple contributing pathophysiologic mechanisms manifesting as symptoms of orthostatic intolerance in the setting of orthostatic tachycardia (increase in heart rate by at least 30 beats per minute upon assuming an upright position) without orthostatic hypotension.”
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“POTS should not be considered a disease but a clinical syndrome or phenotype, with the aforementioned signs (orthostatic tachycardia) and symptoms that worsen and improve with posture change.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: fails — It may be too vague to check against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may be too vague to check against evidence.
In the paper
“Mast cell degranulation causes a variety of vasoactive substances (histamine, prostaglandins, platelet-activating factor) to be released into the circulation, potentially causing excessive vasodilation and blood pooling in the lower extremities (31).”
What the sources say
- Not checked yetcites [31] source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Under normal gravitational conditions, two weeks of strict bedrest resulted in a 17% reduction in plasma volume and a near 10% reduction in stroke volume (41).”
What the sources say
- Not checked yetcites [41] source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“This intolerance primarily manifests as excessive orthostatic tachycardia and reduced QSART (cholinergic sympathetic nerve sweat testing) responses when compared to those of healthy controls (30).”
What the sources say
- Not checked yetcites [30] source
plaincorrelationaln = 39- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Another study in 18 cosmonauts, who had spent several months on a space station, demonstrated that previously healthy individuals can experience moderate hemodynamic changes that almost meet some POTS criteria (average orthostatic heart rate increase by 26 bpm in the absence of orthostatic hypotension), with one individual meeting the orthostatic tachycardia criterion (heart rate increase by 31 b”
What the sources say
- Not checked yetcites [40] source
boostedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Administration of atomoxetine, a selective norepinephrine reuptake inhibitor (NRI), significantly increased the standing heart rate (from 105 bpm to 121 bpm) in POTS patients and resulted in greater symptoms of orthostatic intolerance (46).”
What the sources say
- Not checked yetcites [46] source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Time to peak concentration is 1 h after administration, and pharmacologic effects last 4-5 h (55).”
What the sources say
- Not checked yetcites [55] source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Iatrogenic inhibition of the norepinephrine transporter has also been shown to engender a POTS-like state, increase upright heart rate, and exacerbate symptoms in POTS patients (46-49).”
What the sources say
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“While it can reduce orthostatic tachycardia in POTS patients to a similar extent as midodrine, it lacks a widely available oral dosage form and must be administered subcutaneously (60, 61).”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“However, levels of norepinephrine in POTS patients can increase more than threefold, exceeding 800 pg/ml in many cases, while the increase in healthy controls after assuming an upright position is much more modest at approximately 400-500 pg/ml (36, 43).”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Shannon et al. (13) discovered a single missense mutation (ALA457Pro) in the norepinephrine transporter gene ( SLC6A2 ) that resulted in a 98% loss of function in the transporter and was present in two identical twins with POTS.”
What the sources say
- Not checked yetcites [13] source
plaindirectn = 2- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Administration of a selective serotonin reuptake inhibitor (SSRI), sertraline, also appeared to acutely worsen symptoms in POTS patients, possibly due to nonselective inhibition of the norepinephrine transporter (47).”
What the sources say
- Not checked yetcites [47] source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Although this elevated norepinephrine state may be secondary to partial autonomic neuropathy or hypovolemia, the hallmark of this endophenotype is primary adrenergic excess.”
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Droxidopa is an orally active, synthetic prodrug of norepinephrine that reaches peak plasma concentration in 2 h (57).”
What the sources say
- Not checked yetcites [57] source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“Moreover, this dose did not cause hypertension nor significantly elevate blood pressure in this patient population (54).”
What the sources say
- Not checked yetcites [54] source
plainn = 13- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Regardless, the renin-aldosterone paradox and dysregulation of RAAS play a central role in the pathogenesis of this POTS endophenotype, and clearly would be worsened in the setting of any deconditioning, either voluntary or imposed.”
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: Ang-II is the major effector of the RAAS axis, causing systemic vasoconstriction, raising blood pressure, promoting fluid retention, and is critical for maintaining fluid balance homeostasis through aldosterone secretion.
In the paper
“In healthy subjects, the supine plasma norepinephrine level is approximately 200 pg/ml, and upon standing, it doubles before it plateaus after 7.5 min (43).”
What the sources say
- Not checked yetcites [43] source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Each twin had normal levels of supine plasma norepinephrine (269 pg/ml and 199 pg/ml), but standing plasma norepinephrine exceeded 900 pg/ml.”
What the sources say
- Not checked yetcites [13] source
plainn = 2- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Fedorowski et al. (44) demonstrated that these autoantibodies, in addition to acting like a direct beta-agonist, can also upregulate sympathetic nervous activity through allosteric interactions with the beta-receptors.”
What the sources say
- Not checked yetcites [44] source
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“It has not been well studied prospectively, and a retrospective analysis demonstrated only modest improvement in symptoms (58).”
What the sources say
- Not checked yetcites [58] source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“POTS patients who participated in and completed 3 months of exercise training garnered a significant reduction in orthostatic tachycardia and experienced significant increases in blood volume (42).”
What the sources say
- Not checked yetcites [42] source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“In these studies, doses were initiated at 2.5 mg orally once or twice daily, and titrated up to 10 mg twice daily based on response or side effects with response rates between 60% and 78% (83, 84).”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The clinically heterogeneous nature of POTS makes management inherently difficult.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: fails — It may be too vague to check against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may be too vague to check against evidence.
In the paper
“Patients also noted significant improvements in overall symptoms, specifically symptoms related to vision, tremulousness, and palpitations (69).”
What the sources say
- Not checked yetcites [69] source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Raj et al. (78) demonstrated that the use of propranolol (instant release) at a 20 mg dose significantly reduced orthostatic tachycardia, and improved symptoms compared to placebo up to 4 h after administration.”
What the sources say
- Not checked yetcites [78] source
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Many also report encountering initial skepticism during presentation, being given an incorrect psychiatric diagnosis, and having seen more than ten doctors before the correct diagnosis was made (2).”
What the sources say
- Not checked yetcites [2] source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“but it did improve symptoms, at the expense of elevating blood pressure, in one study of treatment-refractory POTS patients (72).”
What the sources say
- Not checked yetcites [72] source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Pyridostigmine enhances cholinergic activity at both the ganglionic nicotinic and the postganglionic muscarinic acetylcholine receptors, with a likely net increase in parasympathetic nervous system tone (3).”
What the sources say
- Not checked yetcites [3] source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Improving clinician awareness can help improve all of these shortcomings (4).”
What the sources say
- Not checked yetcites [4] source
plainconditional- Asserted: passes — The authors put it forward as true.
- Checkable: fails — It may be too vague to check against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may be too vague to check against evidence.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Lack of strong data and the high expense of erythropoietin limit its routine use in the treatment of POTS.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper relies on this without support.
Targeting the underlying pathophysiologic mechanism in POTS improves clinical outcomes.
“The approach to the treatment of POTS centers on treating the underlying pathophysiologic mechanism.”
The paper relies on this without support.
The three POTS endophenotypes can be reliably distinguished in individual patients so that treatment can be individualized.
“Attempts should be made to discern which pathophysiologic mechanism(s) may be afflicting patients so that treatment regimens can be individualized.”
The paper relies on this without support.
Ang-II is the major effector of the RAAS axis, causing systemic vasoconstriction, raising blood pressure, promoting fluid retention, and is critical for maintaining fluid balance homeostasis through aldosterone secretion.
“Ang-II is the major effector of the RAAS axis, causing systemic vasoconstriction, raising blood pressure, and promoting fluid retention, and it is critical for maintaining fluid balance homeostasis through aldosterone secretion.”
The paper relies on this without support.
Midodrine is efficacious in treating hypovolemic POTS.
“Although midodrine does not directly expand plasma volume, it has been shown to be quite efficacious in treating hypovolemic POTS.”
The paper relies on this without support.
Oral clonidine has a short half-life and can cause a rapid onset-rapid offset phenomenon in some patients.
“Oral clonidine has a short half-life and can cause a rapid onset-rapid offset phenomenon in some patients.”
The paper relies on this without support.
Methyldopa has a longer half-life than oral clonidine and is often better tolerated by POTS patients.
“Methyldopa has a longer half-life than oral clonidine and is often better tolerated by POTS patients.”
Citations
Cites
Sheldon, R. S., Grubb, B. P., Olshansky, B., Shen, W.-K., Calkins, H., Brignole, M., Raj, S. R., Krahn, A. D., Morillo, C. A., Stewart, J. M., et al. (2015) · Heart Rhythm · doi:10.1016/j.hrthm.2015.03.029 · Cited by 1,013
Self-citationOrthostatic Intolerance and Tachycardia Associated with Norepinephrine-Transporter Deficiency
Shannon, J. R., Flattem, N. L., Jordan, J., Jacob, G., Black, B. K., Biaggioni, I., Blakely, R. D., & Robertson, D. (2000) · New England Journal of Medicine · doi:10.1056/nejm200002243420803 · Cited by 594
Hunyady, L., & Catt, K. J. (2006) · Molecular Endocrinology · doi:10.1210/me.2004-0536 · Cited by 541
The neuropathic postural tachycardia syndrome
Jacob, G., Costa, F., Shannon, J. R., Robertson, R. M., Wathen, M., Stein, M., Biaggioni, I., Ertl, A., Black, B., & Robertson, D. (2000) · New England Journal of Medicine · doi:10.1056/nejm200010053431404 · Cited by 398
Cardiac Atrophy After Bed-Rest Deconditioning: A Nonneural Mechanism for Orthostatic Intolerance
Levine, B. D., Zuckerman, J. H., & Pawelczyk, J. A. (1997) · Circulation · doi:10.1161/01.cir.96.2.517 · Cited by 371
Cardiac origins of the postural orthostatic tachycardia syndrome
Fu, Q., VanGundy, T. B., Galbreath, M. M., Shibata, S., Jain, M., Hastings, J. L., Bhella, P. S., & Levine, B. D. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.02.043 · Cited by 329
Shaw, B. H., Stiles, L. E., Bourne, K., Green, E. A., Shibao, C. A., Okamoto, L. E., Garland, E. M., Gamboa, A., Diedrich, A., Raj, V., et al. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12895 · Cited by 326 · cited 3×
“The majority (>90%) of POTS patients are young, white women of childbearing age (2).”
BackgroundSelf-citationPostural Tachycardia Syndrome (POTS)
Raj, S. R. (2013) · Circulation · doi:10.1161/circulationaha.112.144501 · Cited by 320
Self-citationThe epidemic of orthostatic tachycardia and orthostatic intolerance
Robertson, D. (1999) · The American Journal of the Medical Sciences · doi:10.1016/s0002-9629(15)40480-x · Cited by 293
Raj, S. R., Biaggioni, I., Yamhure, P. C., Black, B. K., Paranjape, S. Y., Byrne, D. W., & Robertson, D. (2005) · Circulation · doi:10.1161/01.cir.0000160356.97313.5d · Cited by 286
Self-citation
Research works printed but not linked: 3
- Low PA, 1995, Neurology, 45, S19
- Streeten DH, 1988, J. Lab. Clin. Med., 111, 326
- Raj S, 2014, Heart Rhythm, 11, S30
Cited by
Sorted by citations
Connelly‐Smith, L. S., Alquist, C. R., Aqui, N. A., Hofmann, J. C., Klingel, R., Onwuemene, O. A., Patriquin, C. J., Pham, H. P., Sanchez, A. P., Schneiderman, J., et al. (2023) · Journal of Clinical Apheresis · doi:10.1002/jca.22043 · Cited by 751
ASIA syndrome and endocrine autoimmune disorders
Bragazzi, N. L., Hejly, A., Watad, ., Adawi, M., Amital, H., & Shoenfeld, Y. (2020) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2020.101412 · Cited by 134
Taub, P. R., Zadourian, A., Lo, H. C., Ormiston, C. K., Golshan, S., & Hsu, J. C. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.12.029 · Cited by 122
Raj, S. R., Bourne, K. M., Stiles, L. E., Miglis, M. G., Cortez, M. M., Miller, A. J., Freeman, R. L., Biaggioni, I., Rowe, P. C., Sheldon, R. S., et al. (2021) · Autonomic Neuroscience · doi:10.1016/j.autneu.2021.102836 · Cited by 63
Self-citationEffect of High Dietary Sodium Intake in Patients With Postural Tachycardia Syndrome
Garland, E. M., Gamboa, A., Nwazue, V. C., Celedonio, J. E., Paranjape, S. Y., Black, B. K., Okamoto, L. E., Shibao, C. A., Biaggioni, I., Robertson, D., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.03.005 · Cited by 65
Self-citation
Metadata
- Authors
- Mar, P. L., & Raj, S. R.
- Affiliations
- Saint Louis University (US)
- University of Calgary (CA)
- Venue
- Annual Review of Medicine
- Publisher
- Annual Reviews
- Published
- 2020-01-27
- Volume
- 71
- Issue
- 1
- Pages
- 235-248
- ISSN
- 0066-4219 (ISSN-L)
- 1545-326X
- OpenAlex
- W2967501582
- Semantic Scholar
- 392e517d5ad05ac895e6046186443346358a7d07
- Cited by
- 122
- References
- 85
- Citations by year
- 2026: 21 · 2025: 21 · 2024: 23 · 2023: 16 · 2022: 18 · 2021: 13 · 2020: 10
- FWCI
- 2.11
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Annual Review of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (UL1TR000445)
- Canadian Institutes of Health Research (42426_1)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Syncope and Autonomic Disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Rate Variability and Autonomic Control
- Health Sciences › Medicine › Clinical Neurology › Long-Term Effects of COVID-19
- Keywords
- postural orthostatic tachycardia syndrome, orthostatic intolerance, autonomic neuropathy, hypovolemia, hyperadrenergic state, pathophysiology, compression garments, abdominal binder, vasoconstrictors, exercise therapy, volume expansion, beta-blockers, norepinephrine reuptake inhibitors, personalized treatment
- MeSH terms
- Ivabradine, Adrenergic beta-Antagonists, Cardiovascular Agents, Clonidine, Combined Modality Therapy, Female, Humans, Male, Methyldopa, Quality of Life, Severity of Illness Index, Survival Analysis, Treatment Outcome, Risk Assessment, Postural Orthostatic Tachycardia Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
